Hot Issues on BioMarin Pharmaceutical Inc. Earnings Conference Call – Motley Fool

Hot Issues on BioMarin Pharmaceutical Inc. Earnings Conference Call
Motley Fool
As expected, BioMarin Pharmaceuticals‘ (NASDAQ: BMRN ) first quarter earnings release was focused on two hot issues: sales of Vimizim and the approvability of its Duchenne muscular dystrophy drug, drisapersen. Both discussions were quite positive.
BioMarin Pharmaceutical (BMRN) Earnings Report: Q1 2015 Conference Call TheStreet.com
BioMarin Pharmaceutical’s (BMRN) CEO Jean-Jacques Bienaime on Q1 2015 Seeking Alpha
BioMarin Pharmaceutical (BMRN) Announces Quarterly Earnings ResultsThe Legacy
Dakota Financial News -Street Report -Investor Newswire
all 19 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd